CH667592A5 - 9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen. - Google Patents

9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen. Download PDF

Info

Publication number: CH667592A5
Authority: CH; Switzerland
Prior art keywords: composition according; dihydroergotamine; dergocrin; release; fatty
Prior art date: 1985-02-05

Application number

CH296/86A

Other languages

German (de)

English (en)

Inventor

Othmar Zueger

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-02-05

Filing date

1986-01-27

Publication date

1988-10-31

1985-02-05 Priority claimed from GB858502889A external-priority patent/GB8502889D0/en

1985-07-12 Priority claimed from GB858517604A external-priority patent/GB8517604D0/en

1986-01-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-10-31 Publication of CH667592A5 publication Critical patent/CH667592A5/de

Links

239000008194 pharmaceutical composition Substances 0.000 title description 3
239000000203 mixture Substances 0.000 claims description 41
229960004704 dihydroergotamine Drugs 0.000 claims description 22
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 20
239000000463 material Substances 0.000 claims description 15
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 10
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
229960003133 ergot alkaloid Drugs 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
238000013270 controlled release Methods 0.000 claims description 4
-1 fatty acid ester Chemical class 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
229930015720 peptide alkaloid Natural products 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
239000002775 capsule Substances 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 14
239000003826 tablet Substances 0.000 description 14
238000011282 treatment Methods 0.000 description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
239000008101 lactose Substances 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 8
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 8
229940074979 cetyl palmitate Drugs 0.000 description 8
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
235000013305 food Nutrition 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000000377 silicon dioxide Substances 0.000 description 7
230000002035 prolonged effect Effects 0.000 description 6
235000012239 silicon dioxide Nutrition 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000007963 capsule composition Substances 0.000 description 5
239000000470 constituent Substances 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
239000012458 free base Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
235000021152 breakfast Nutrition 0.000 description 3
239000004359 castor oil Substances 0.000 description 3
DEQITUUQPICUMR-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 DEQITUUQPICUMR-HJPBWRTMSA-N 0.000 description 3
229960004318 dihydroergocristine Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
208000001407 Vascular Headaches Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000001175 calcium sulphate Substances 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
230000004087 circulation Effects 0.000 description 2
229940069063 dihydro-beta-ergocryptine Drugs 0.000 description 2
SBFXHXZNBNFPHV-PXXBSISHSA-N epicriptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)[C@H](C)CC)C(C)C)=C3C2=CNC3=C1 SBFXHXZNBNFPHV-PXXBSISHSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004880 explosion Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
125000005908 glyceryl ester group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
239000000416 hydrocolloid Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
230000002746 orthostatic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
206010000599 Acromegaly Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
240000000662 Anethum graveolens Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000206575 Chondrus crispus Species 0.000 description 1
241001440269 Cutina Species 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010017600 Galactorrhoea Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000027109 Headache disease Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
229920003095 Methocel™ K15M Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
241000428199 Mustelinae Species 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
206010036832 Prolactinoma Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
240000001058 Sterculia urens Species 0.000 description 1
235000015125 Sterculia urens Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000006651 lactation Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CH296/86A 1985-02-05 1986-01-27 9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen. CH667592A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB858502889A GB8502889D0 (en)	1985-02-05	1985-02-05	Co-dergocrine compositions
GB858517604A GB8517604D0 (en)	1985-07-12	1985-07-12	Dihydroergotamine compositions

Publications (1)

Publication Number	Publication Date
CH667592A5 true CH667592A5 (de)	1988-10-31

Family

ID=26288767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH296/86A CH667592A5 (de)	1985-02-05	1986-01-27	9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen.

Country Status (24)

Country	Link
JP (1)	JPS61183225A (da)
KR (1)	KR920010388B1 (da)
AU (1)	AU597570B2 (da)
BE (1)	BE904152A (da)
CA (1)	CA1263087A (da)
CH (1)	CH667592A5 (da)
CY (1)	CY1604A (da)
DE (1)	DE3602577A1 (da)
DK (1)	DK167138B1 (da)
ES (1)	ES8800040A1 (da)
FR (1)	FR2576787B1 (da)
GB (1)	GB2170407B (da)
GR (1)	GR860310B (da)
HK (1)	HK57191A (da)
HU (1)	HU195729B (da)
IE (1)	IE59293B1 (da)
IT (1)	IT1191255B (da)
LU (1)	LU86289A1 (da)
NL (1)	NL8600161A (da)
NZ (1)	NZ215020A (da)
PH (1)	PH23384A (da)
PT (1)	PT81954B (da)
SE (1)	SE8600496L (da)
SG (1)	SG56191G (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2610827B1 (fr) *	1987-02-18	1991-09-13	Pf Medicament	Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
SI8710406B (sl) *	1987-03-11	1998-08-31	Lek	Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
US7771746B2 (en)	1999-12-03	2010-08-10	Polichem Sa	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
EP1512403A1 (en) *	1999-12-03	2005-03-09	Polichem S.A.	Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6696491B2 (en)	2000-05-12	2004-02-24	Meracol Corporation Limited	Treating irritable bowel syndrome or disease
NZ504526A (en) *	2000-05-12	2003-05-30	Meracol Corp Ltd	Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate
CA2408541C (en) *	2000-05-12	2009-07-28	Meracol Corporation Limited	Treating eczema and/or psoriasis
US20030153620A1 (en)	2000-05-12	2003-08-14	Meakin Timothy David	Treating eczema and/or psoriasis
WO2003026640A1 (en) *	2001-09-28	2003-04-03	Meracol Corporation Limited	Treating food allergies and/or food intolerances
CN111297815B (zh) *	2020-04-29	2022-04-15	宝利化（南京）制药有限公司	一种甲磺酸二氢麦角碱缓释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3147187A (en) *	1962-09-10	1964-09-01	Don Hall Lab	Sustained release pharmaceutical
CH630257A5 (en) *	1975-03-17	1982-06-15	Hoffmann La Roche	Sustained release formulation
DE3124983A1 (de) *	1981-06-25	1983-01-20	Meditest Inst Fuer Medizinisch	Arzneiformen zur oralen verabreichung
CH649300A5 (de) *	1981-08-07	1985-05-15	Sandoz Ag	Ergopeptinderivate, ihre herstellung und verwendung.
US4369172A (en) *	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3303616A1 (de) *	1982-02-12	1983-08-25	Sandoz-Patent-GmbH, 7850 Lörrach	Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zubereitungen
US4421736A (en) *	1982-05-20	1983-12-20	Merrel Dow Pharmaceuticals Inc.	Sustained release diethylpropion compositions
JPS604120A (ja) *	1983-06-22	1985-01-10	Shionogi & Co Ltd	作用持続型ピナシジル製剤
GB2154874B (en) *	1984-02-29	1987-11-04	Sandoz Ltd	Bromoscriptine compositions
GB8413795D0 (en) *	1984-05-30	1984-07-04	Sandoz Ltd	Organic compounds

1986
- 1986-01-24 HU HU86361A patent/HU195729B/hu not_active IP Right Cessation
- 1986-01-24 NL NL8600161A patent/NL8600161A/nl not_active Application Discontinuation
- 1986-01-27 CH CH296/86A patent/CH667592A5/de not_active IP Right Cessation
- 1986-01-29 DE DE19863602577 patent/DE3602577A1/de not_active Ceased
- 1986-01-31 FR FR868601477A patent/FR2576787B1/fr not_active Expired - Lifetime
- 1986-02-03 BE BE1/011431A patent/BE904152A/fr not_active IP Right Cessation
- 1986-02-03 GR GR860310A patent/GR860310B/el unknown
- 1986-02-03 AU AU52942/86A patent/AU597570B2/en not_active Ceased
- 1986-02-03 IE IE29186A patent/IE59293B1/en not_active IP Right Cessation
- 1986-02-03 GB GB08602602A patent/GB2170407B/en not_active Expired
- 1986-02-03 CA CA000501011A patent/CA1263087A/en not_active Expired
- 1986-02-03 DK DK052086A patent/DK167138B1/da not_active IP Right Cessation
- 1986-02-03 PT PT81954A patent/PT81954B/pt not_active IP Right Cessation
- 1986-02-03 NZ NZ215020A patent/NZ215020A/xx unknown
- 1986-02-03 KR KR1019860000698A patent/KR920010388B1/ko not_active Expired
- 1986-02-04 PH PH33379A patent/PH23384A/en unknown
- 1986-02-04 ES ES551635A patent/ES8800040A1/es not_active Expired
- 1986-02-04 LU LU86289A patent/LU86289A1/fr unknown
- 1986-02-04 JP JP61023666A patent/JPS61183225A/ja active Pending
- 1986-02-04 SE SE8600496A patent/SE8600496L/ not_active Application Discontinuation
- 1986-02-05 IT IT47620/86A patent/IT1191255B/it active
1991
- 1991-07-16 SG SG561/91A patent/SG56191G/en unknown
- 1991-07-25 HK HK571/91A patent/HK57191A/xx unknown
1992
- 1992-04-03 CY CY1604A patent/CY1604A/en unknown

Also Published As

Publication number	Publication date
GB2170407A (en)	1986-08-06
FR2576787A1 (fr)	1986-08-08
CA1263087A (en)	1989-11-21
PT81954A (en)	1986-03-01
DK167138B1 (da)	1993-09-06
IT8647620A0 (it)	1986-02-05
JPS61183225A (ja)	1986-08-15
DK52086D0 (da)	1986-02-03
GR860310B (en)	1986-05-27
IE860291L (en)	1986-08-05
ES551635A0 (es)	1987-10-16
NL8600161A (nl)	1986-09-01
SE8600496L (sv)	1986-08-06
IT1191255B (it)	1988-02-24
HU195729B (en)	1988-07-28
BE904152A (fr)	1986-08-04
PH23384A (en)	1989-07-26
IE59293B1 (en)	1994-02-09
PT81954B (pt)	1988-07-01
ES8800040A1 (es)	1987-10-16
KR860006265A (ko)	1986-09-09
HK57191A (en)	1991-08-02
AU5294286A (en)	1986-08-14
DK52086A (da)	1986-08-06
KR920010388B1 (ko)	1992-11-27
HUT41984A (en)	1987-06-29
SG56191G (en)	1991-08-23
FR2576787B1 (fr)	1990-01-12
DE3602577A1 (de)	1986-08-28
LU86289A1 (fr)	1986-09-02
NZ215020A (en)	1989-07-27
GB2170407B (en)	1988-10-26
AU597570B2 (en)	1990-06-07
SE8600496D0 (sv)	1986-02-04
GB8602602D0 (en)	1986-03-12
CY1604A (en)	1992-04-03

Legal Events

Date	Code	Title	Description
1994-09-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE69623634T2 (de)	2003-05-22	Pharmazeutische zusammensetzung von l-dopa ethyl ester
DE3879080T2 (de)	1993-07-15	Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.
EP0656776B1 (en)	1996-03-20	Multilayer controlled release tablets containing both naproxen and naproxen sodium salt
DE69418252T2 (de)	1999-11-04	Stabilisierte, feste pharmazeutische Zubereitung, die Dextromethorphan Phenylpropanolamine und Coffein enthält
DE3719818C2 (de)	1997-02-13	Pharmazeutische Zusammensetzung
EP0682945A2 (de)	1995-11-22	Orale Retard-Präparation
DE2224534B2 (de)	1977-10-20	Pharmazeutisches praeparat mit langsamer wirkstoffabgabe
DE4028906A1 (de)	1992-03-19	Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DE69814850T2 (de)	2004-03-11	Paracetamol enthaltende schlickbare tablette
DE69737373T2 (de)	2007-06-21	Östroprogestatives Antikonzeptionsmittel
DE3603564A1 (de)	1986-08-14	Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung
CH667592A5 (de)	1988-10-31	9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen.
DE3517820C2 (da)	1992-07-30
DE3524003A1 (de)	1987-01-08	Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung
DE2732335A1 (de)	1978-02-02	Neue pharmazeutische zusammensetzung und verfahren zu deren herstellung
US5069911A (en)	1991-12-03	Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
HU225779B1 (en)	2007-08-28	Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
AT388101B (de)	1989-05-10	Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstofffreisetzung
DE3505743C2 (de)	1995-02-16	Bromocriptin enthaltende Zusammensetzungen
DE19849737A1 (de)	2000-05-04	Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
DE3632201C2 (de)	1997-05-07	Pharmazeutische Zusammensetzung mit retardierter Freisetzung des Wirkstoffes
EP0315197A1 (de)	1989-05-10	Oral anzuwendende Arzneiform zur einmal täglichen Behandlung der Hypertonie mit Diltiazemhydrochlorid
DE2621906C2 (da)	1988-04-21
DD249186A1 (de)	1987-09-02	Herstellungsverfahren einer neuen glibenclamid-arzneiform mit hoher bioverfuegbarkeit
DE3005029C2 (de)	1987-02-12	Antihypertensive pharmazeutische Zubereitungen